CNBC’s David Faber says he’s heard “nothing” about a potential suitor showing interest in acquiring Bristol-Myers Squibb (BMY) as well as a possible activist getting involved. Faber attributes these concerns for Celgene (CELG) trading at a wide deal spread.
https://thefly.com/landingPageNews.php?id=2853213
https://thefly.com/landingPageNews.php?id=2853213
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.